Royalty Pharma RPRX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's total liabilities & equity?
- Royalty Pharma (RPRX) reported total liabilities & equity of $19.82B in Q1 2026.
- How has Royalty Pharma's total liabilities & equity changed year-over-year?
- Royalty Pharma's total liabilities & equity increased by 12.5% year-over-year, from $17.61B to $19.82B.
- What is the long-term trend for Royalty Pharma's total liabilities & equity?
- Over 5 years (2020 to 2025), Royalty Pharma's total liabilities & equity has grown at a 4.1% compound annual growth rate (CAGR), from $16.02B to $19.62B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.